Arsenic can induce apoptosis and is an efficient drug for the treatment of
acute promyelocytic leukemia. Currently, clinical studies are investigating
arsenic as a therapeutic agent for a variety of
malignancies. In this study, Hodgkin/Reed-Sternberg (HRS) cell lines served as model systems to characterize the role of
nuclear factor-kappaB (
NF-kappaB) in
arsenic-induced apoptosis.
Arsenic rapidly down-regulated constitutive
IkappaB kinase (IKK) as well as
NF-kappaB activity and induced apoptosis in HRS cell lines containing functional IkappaB
proteins. In these cell lines, apoptosis was blocked by inhibition of
caspase-8 and caspase-3-like activity. Furthermore,
arsenic treatment down-regulated
NF-kappaB target genes, including
tumor necrosis factor-alphareceptor-associated factor 1 (
TRAF1), c-IAP2,
interleukin-13 (IL-13), and CCR7. In contrast, cell lines with mutated, functionally inactive IkappaB
proteins or with a weak constitutive IKK/
NF-kappaB activity showed no alteration of the
NF-kappaB activity and were resistant to
arsenic-induced apoptosis. A direct role of the
NF-kappaB pathway in
arsenic-induced apoptosis is shown by transient overexpression of NF-kappaB-p65 in L540Cy HRS cells, which protected the cells from
arsenic-induced apoptosis. In addition, treatment of NOD/SCID mice with
arsenic trioxide induced a dramatic reduction of xenotransplanted L540Cy Hodgkin
tumors concomitant with
NF-kappaB inhibition. We conclude that inhibition of
NF-kappaB contributes to
arsenic-induced apoptosis. Furthermore, pharmacologic inhibition of the IKK/
NF-kappaB activity might be a powerful treatment option for
Hodgkin lymphoma.